Evinacumab

Summary

Evinacumab (CHEMBL3545191) is an approved antibody (ATC C10AX17); indicated across 6 conditions including familial hypercholesterolemia and cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: C10AX17
• Indications: 6 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545191
Name	Evinacumab
Type	Antibody
Max phase	4
ATC	C10AX17

Also known as: Evinacumab, Evinacumab dgnb, Evinacumab-dgnb, Evkeeza, REGN-1500, REGN1500, EVINACUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
familial hypercholesterolemia	4	MONDO:0005439	EFO:0004911
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
hypertriglyceridemia	2	MONDO:0005347	EFO:0004211
metabolic disease	1	MONDO:0005066	EFO:0000589

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2	4
PHASE1	3
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03399786	PHASE3	COMPLETED	Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
NCT03409744	PHASE3	COMPLETED	Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
NCT04233918	PHASE3	COMPLETED	Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia
NCT05611528	PHASE3	COMPLETED	Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia
NCT07271186	PHASE2	RECRUITING	Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
NCT03175367	PHASE2	COMPLETED	Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
NCT03452228	PHASE2	COMPLETED	Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
NCT04863014	PHASE2	TERMINATED	Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
NCT01749878	PHASE1	COMPLETED	Study to Assess the Safety and Tolerability of Single Doses of REGN1500
NCT02107872	PHASE1	COMPLETED	Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
NCT03146416	PHASE1	COMPLETED	Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
NCT06500598	Not specified	APPROVED_FOR_MARKETING	Compassionate Use of Evinacumab

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).